Lilly signs licensing deal with Mediar for IPF drug
Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...
FierceBiotech1d
Eli Lilly pushes into pulmonary fibrosis with $99M deal for Mediar's midphase prospect
Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...
Contract Pharma1d
Mediar, Lilly Enter Global Licensing Agreement for WISP1 Antibody
A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.
BioSpace1d
Lilly Makes $780M+ IPF Play with Mediar Partnership
Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...
ENDPOINTS NEWS1d
Lil­ly ven­tures in­to pul­monary fi­bro­sis with start­up Me­di­ar
Boston-area startup Mediar Therapeutics is teaming up with Eli Lilly on a new drug for idiopathic pulmonary fibrosis. Lilly — ...